Literature DB >> 24415976

Pathway-oriented concepts in adjuvant and neoadjuvant breast cancer therapy.

Gunter von Minckwitz1, Caterina Fontanella2.   

Abstract

Entities:  

Year:  2013        PMID： 24415976      PMCID： PMC3808220          DOI： 10.1159/000354788

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  6 in total

Review 1.  Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications.

Authors:  Mario Giuliano; Meghana V Trivedi; Rachel Schiff
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

Review 2.  Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.

Authors:  Shira Peleg Hasson; Tami Rubinek; Larysa Ryvo; Ido Wolf
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

Review 3.  How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Authors:  Ana Catarina Pinto; Evandro de Azambuja; Martine Piccart-Gebhart
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

4.  Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

Authors:  Jens Huober; Peter A Fasching; Claus Hanusch; Mahdi Rezai; Holger Eidtmann; Kornelia Kittel; Jörn Hilfrich; Kathrin Schwedler; Jens-Uwe Blohmer; Hans Tesch; Bernd Gerber; Cornelia Höß; Sherko Kümmel; Christine Mau; Christian Jackisch; Fariba Khandan; Serban Dan Costa; Petra Krabisch; Sibylle Loibl; Valentina Nekljudova; Michael Untch; Gunter von Minckwitz
Journal:  Eur J Cancer       Date:  2013-03-27       Impact factor: 9.162

5.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

Authors:  Gunter von Minckwitz; Michael Untch; Jens-Uwe Blohmer; Serban D Costa; Holger Eidtmann; Peter A Fasching; Bernd Gerber; Wolfgang Eiermann; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Gottfried E Konecny; Carsten Denkert; Valentina Nekljudova; Keyur Mehta; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

6.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.